Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 515-520 , October 2004

The treatment of brain metastases in melanoma patients

  • D. Bafaloukos

      Affiliations

    • Department of Oncology, Metropolitan Hospital, 9 E. Malariou Str., N. Faliro 185 47, Greece
    • Corresponding Author InformationCorresponding author. Tel.: +30-210-429-6620; fax: +30-210-429-6621
    • ,
  • H. Gogas

      Affiliations

    • First Department of Medicine, University of Athens, Aghiou Thoma 17, 115 27, Athens, Greece

References 

  1. Clouston PD, De Angelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann. Neurol. 1992;31:268–273
  2. Wen Py, Loeffler JS. Management of brain metastases. Oncology. 1999;13:941–961
  3. Davey P. Brain metastases. Curr. Probl. Cancer. 1999;23:59–98
  4. Posner JB. Management of brain metastases. Reu Nelson. 1992;148:477–487
  5. Johnson JD, Young B. Demographics of brain metastases. Neurosurg. Clin. North Am. 1996;7:337–344
  6. Zimm S, Wampler GL, Stablein D, et al.  Intracerebral metastases in solid tumour patients: natural history and results of treatment. Cancer. 1981;48:384–394
  7. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 ptients with brain metastases from malignant melanoma. J. Neurosurg. 1998;88:11–20
  8. Amer M, Al-Sarraf M, Vaitkevicus V. Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg. Gynecol. Obstet. 1979;149:687–692
  9. Budman D, Camacho E, Wittes R. The current causes of death in patients with malignant melanoma. Eur. J. Cancer. 1978;14:327–330
  10. Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br. J. Cancer. 1997;76:256–259
  11. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma metastases, bone metastases and spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 1988;15:859–864
  12. Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnet GH. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer. 2002;94:2265–2272
  13. Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J. Neurosurg. 2000;93:9–18
  14. Skibber JM, Soong SJ, Austin L, et al.  Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann. Surg. Oncol. 1996;3:118–123
  15. Somaza S, Kondziolka D, Lunsford LD, et al.  Stereotactic radiosurgery for cerebral metastatic melanoma. J. Neurosurg. 1993;79:661–666
  16. Mori Y, Kondziolka D, Flickinger JC, et al.  Stereotactic radiosurgery for cerebral metastatic melanoma effecting local disease control and survival. Int. J. Radiat. Oncol. Biol. Phys. 1998;42:581–591
  17. Seung SK, Sneed PK, Mc Dermott MW, et al.  Gamma knife radiosurgery for malignant melanoma brain metastases. Cancer J. Sci. Am. 1998;4:103–109
  18. Gieger M, Wu JK, Ling MN, et al.  Response to intracranial melanoma metastases to sterotactic radiosurgery. Radiat. Oncol. Invest. 1997;5:72–80
  19. Grob JJ, Regis J, Laurans R, et al.  Radiosurgery without whole brain radiotherapy in melanoma metastases. Club de Cancerologie Cutanee. Eur. J. Cancer. 1998;34:1187–1192
  20. Jacquillat C, Khayat D, Banzer P, et al.  Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:873–1878
  21. Kleeberg UR, Engel E, Israels P, et al.  Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicenter phase II trial of the EORTC. Melanoma Cooperative Group (MCG). Melanoma Res. 1995;5:195–200
  22. Khayat D, Giroux B, Berille J, et al.  Fotemustine in the treatment of brain primary tumours and metastases. Cancer. Invest. 1994;12:414–420
  23. Falkson Cl, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest. New Drugs. 1994;12:251–254
  24. Newlands ES, Blackledge GR, Slack JA, et al.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer. 1992;65:287–291
  25. Stevens MF, Hickman JA, Langdon SP, et al.  Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3 methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4 (3H) one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to decarbazine. Cancer Res. 1987;47:5846–5852
  26. Newlands ES, Stevens MF, Wedge SR, et al.  Temozolomide: a review of its discovery chemical properties, pre clinical developments and clinical trials. Cancer Treat. Rev. 1997;23:35–61
  27. Baker SD, Wirth M, Statkevich P, et al.  Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin. Cancer Res. 1999;5:309–317
  28. Patel M, McCully C, Godwin K, et al.  Plasma and cerebrospinal fluid pharmacokinetics of temozolomde. Proc. Am. Soc. Clin. Oncol. 1995;14:461; [Abstract]
  29. Marzolini C, Decosterd LA, Shen F, et al.  Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients. Comparison of oral intravenous, and hepatic intra-arterial administration. Cancer Chemother. Pharmacol. 1998;42:433–440 [Published erratum appears in Cancer Chemother Pharmacol 1999;43:439–40]
  30. Meikle SR, Matthews JC, Brock CS, et al.  Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother. Pharmacol. 1998;42:183–193
  31. Bleehen NM, Newlands ES, Lee SM, et al.  Cancer Research Campain phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol. 1995;13:910–913
  32. Middleton MR, Grob JJ, Aaronson N, et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000;18:158–166
  33. Franke W, Neumann N, Richter-Hintz D, et al.  Temozolomide-a promising agent in the therapy of brain metastases in malignant melanoma. Proc. ASCO. 2000;19: [Abstract 2268A]
  34. Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. NEJM. 2001;345:621–622
  35. Janinis J, Kapelari K, Efstathiou E, et al.  A pilot study of temozolomide as first line therapy of central nervous system metastses from malignant melanoma. J. BUON. 2000;5:277–280
  36. Bafaloukos D, Gogas H, Georgoulias V, et al.  Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol. 2002;20:420–425
  37. Bafaloukos D, Ioannovits J, Kalofonos Ch, et al. Temozolomide (T) plus cisplatin (P) vs Temozolomide in patients with advanced melanoma: A Randomized, phase II study of the Hellenic cooperative oncology group. In: Proceedings of the 4th International Conference in the adjuvant therapy of malignant melanoma. March 15–16 2002, London
  38. Gogas H, Christodoulou CH, Molfeta A, et al.  Cerebral metastases from melanoma. The effect of temozolomide-based chemotherapy. Ann. Oncol. 2003;(Suppl 3):62; [Abstract 97P]
  39. Siena S, Landonio G, Baietta E, et al. Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer and non-small cell lung cancer. In: Proc ASCO; 2003 [Abstract 407]
  40. Hwu WJ, Krown SE, Mennell JH, et al.  Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 2003;21:3351–3356
  41. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001;2:634–635
  42. Stupp R, Maillard I, Pica A, et al.  Daily temozolomide and concomitant radiotherapy followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme: A well tolerated and promising regimen. Proc. Am. Soc. Clin. Oncol. 1999;18:154a; [Abstract 592]
  43. Newlands ES, Wedge SR, Porteous JK, et al.  Temozolomide: Drug scheduling in vivo and in combination with radiation. Proc. Am. Soc. Clin. Oncol. 1997;16:393a; [Abstract 1403]
  44. Margolin K, Atkins MB, Thompson JA, et al.  Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 2002;128:214–218

PII: S0305-7372(04)00094-5

doi: 10.1016/j.ctrv.2004.05.001

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 515-520 , October 2004

Article Tools